CD274 and non-small cell lung carcinoma: However, in the recently published Checkmate 227 update reporting the 5-year clinical outcomes of the trial, comparing first-line immunotherapy combination to chemotherapy in metastatic NSCLC, immunotherapy achieved substantial long-term clinical benefit regardless of PD-L1 expression.